Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001731122-25-000514
Filing Date
2025-04-02
Accepted
2025-04-02 21:45:23
Documents
1
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3867
  Complete submission text file 0001731122-25-000514.txt   5353
Mailing Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111
Business Address 630 5TH AVENUE 20TH FLOOR NEW YORK NY 10111 844-689-3939
ANAVEX LIFE SCIENCES CORP. (Issuer) CIK: 0001314052 (see all company filings)

EIN.: 980608404 | Fiscal Year End: 0930
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address PO BOX MUENSTEREIFELER ST. COLOGNE 2M 50937
Business Address
Velden Claus Vander (Reporting) CIK: 0001733908 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37606 | Film No.: 25807269